Trial reportEuropean journal of medical research2024
Effectiveness of a multimodal therapy protocol for the management of allergic rhinitis: a randomized controlled trial.
Trial report in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study endeavors to comprehensively assess the efficacy of a multimodal therapy protocol in the management and treatment of allergic rhinitis.
methodsThis study employed a randomized controlled trial design, enrolling a total of 100 patients, who were randomly assigned to either the experimental group (receiving multimodal therapy) or the control group (receiving standard treatment), with 50 patients in each group. All enrolled patients were diagnosed based on standard guidelines for allergic rhinitis. Standardized AR questionnaires were used to assess patients' symptoms. The primary outcome measures included the time of nasal allergy symptom relief and treatment effectiveness. Statistical software will be utilized for data analysis.
resultsThe experimental group showed shorter relief times for symptoms such as nasal itching, nasal congestion, rhinorrhea, and sneezing compared to the control group. Specifically, the relief times for nasal itching, nasal congestion, rhinorrhea, and sneezing in the experimental group were (3.16 ± 0.45) days, (2.68 ± 0.55) days, (2.51 ± 0.23) days, and (3.41 ± 0.31) days, respectively, while the control group's respective times were (5.13 ± 0.77) days, (4.35 ± 0.71) days, (4.85 ± 0.63) days, and (6.73 ± 0.99) days (P < 0.05). After treatment, the total effective rate in the experimental group reached 90.0%, significantly higher than the 66.0% in the control group (P < 0.05).
conclusionsThe results of this study indicate that multimodal therapy not only exhibits significant effectiveness in the management of allergic rhinitis but also holds potential advantages in improving patients' quality of life. These findings provide a new perspective for the treatment of AR and may have significant implications for the design and optimization of future AR treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.